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1. Introduction 
The need for replacement of damaged or malfunctioning organs or tissues in the human 
body has led through intense and innovative research during the past century to the 
development of materials and devices which are compatible with living tissues. Materials’ 
compatibility consists in their capability to be accepted by the body when implanted and in 
contact with other tissues and body fluids. These materials, known as biomaterials, are the 
fundamental tools for engineering implantable devices dedicated to function in a specific 
way that substitutes corresponding function of the tissues or organs replaced due to 
malfunction, in synergism with the surrounding biological environment. Bone fracture 
healing by the incorporation of plates was known as early as the beginning of the century. 
Implants to replace heart valves and hip joints have been reported in the early 60s (Park & 
Lakes, 1992). Among the problems recorded when the first implants were employed were 
corrosion, mechanical failure and rejection by the body. The latter remains the main 
problem in the development of novel biomaterials which can be used as implants. 
Biomaterials now play a major role in replacing or improving the function of every major 
body system (skeletal, circulatory, nervous, etc.). Commonly employed implants include 
orthopedic devices such as total knee and hip joint replacements, spinal implants, and bone 
fixators; cardiac implants such as artificial heart valves and pacemakers; soft tissue implants 
such as breast implants and injectable collagen for soft tissue augmentation; and dental 
implants to replace teeth/root systems and bony tissue in the oral cavity.  
When a man-made material is placed in the human body, tissue reacts to the implant in a 
variety of ways depending on the material type and function. The mechanism of tissue 
attachment depends on the tissue response to the implant surface. In general, materials can 
be placed into three classes that represent the tissue response they elicit: inert, bioresorbable, 
and bioactive. Inert materials such as titanium and alumina (Al2O3) are nearly chemically 
inert in the body and exhibit minimal chemical interaction with adjacent tissue. A fibrous 
tissue capsule will normally form around inert implants. Tissue attachment with inert 
materials can be through tissue growth into surface irregularities, by bone cement, or by 
press fitting into a defect. This morphological fixation is not ideal for the long-term stability 
of permanent implants and often becomes a problem with orthopedic and dental implant 
applications. Bioresorbable materials, such as tricalcium phosphate and polylactic-
www.intechopen.com
 Aortic Valve Surgery 
 
58 
polyglycolic acid copolymers, are designed to be slowly degraded under the biological-
biochemical action of the living organism in bioresorbable products (like water, ions of 
electrolytes or CO2), replaced by living tissue (such as bone or soft tissues in tissue 
engineering) or liberating drugs, as in drug-delivery applications. Bioactive materials bond 
to surrounding tissues (like bone or soft tissues) through a time-dependent, kinetic 
modification of the surface triggered by their contact and function after implantation with 
parts of living organism. In particular, ion-exchange reactions or ion incorporation into the 
crystal lattice between the bioactive implant and the surrounding body fluids results in the 
formation of a biologically active interface layer on the implant surface responsible for the 
relatively strong interfacial bonding.  
1.1 Anatomy of the normal aortic valve 
The aortic valve (figure 1) is composed of three components: the annulus, the cusps or 
leaflets and the commissures. The annulus of the valve, in contrast to this of atrioventricular 
valves, does not located at the same level. Here, the annulus consists of ventriculo-arterial 
junction and is oriented in a curvilinear, semilunar fashion. It consists of three almost 
semicircular dense fibrous collagen structures forming three scallops, the whole encircling 
the ventriculo-aortic junction like a coronet. The three aortic leaflets are folds of 
endocardium with a central lamina fibrosa, which is locally thickened. Each leaflet is 
attached to the aortic wall (its upper part) and to the left ventricle (its lowest part or nadir of  
 
 
Fig. 1. Anatomy of aortic valve construct. a. View from aorta & b. from left ventricle. c: View 
from aorta, showing leaflet junction, sinus of Valsalva and coronary ostium. Pictures are 
from a porcine aortic valve, of similar anatomy with human aortic valve 
 
 
Fig. 2. Histological sections (a and b) and SEM microphotograph (c) of valvular leaflet tissue, 
demonstrating its multilaminate, 3D fiber reinforced composite structure, make it suitable 
for the complicated leaflet movements during valve function. F: Fibrosa, S: Spongiosa & V: 
Ventricularis 
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the leaflet). Leaflets are multilaminate composite tissue structures of 3 layers (Figure 2.): the 
ventricularis, composed of elastin- rich fibers aligned in a radial direction, perpendicular to 
the leaflet margin, the fibrosa, on the aortic side of the leaflet, comprising primarily 
fibroblasts and collagen fibers arranged circumferentially, parallel to the leaflet margin and 
the spongiosa, a layer of loose connective tissue at the base of the leaflet, between the fibrosa 
and ventricularis, composed of fibroblasts, mesenchymal cells, and a glycosaminoglycan 
(GAG) rich organic matrix. This composite tissue structure provides tensile strength and 
pliability to the leaflets for decades of repetitive motion per minute (Freeman & Otto, 2005). 
The aortic surface of each leaflet is rougher than its ventricular surface. 
 
 
Fig. 3. Schematic representation of the three aortic valve commissures in natural and open 
configuration (acknowledged art work by G. Athanassiou) 
The commissures (figure 3) form tall, peaked spaces between the attachments of 
neighbouring cusps, and reach the so-called aortic sino-tubular junction. The latter is a 
ridge, called also “supraortic ridge” that separates the sinus and tubular portions of the 
ascending aorta (Malouf et al., 2008). The commissure between the right and non-coronary 
(or posterior) aortic leaflet overlies the membranous septum and corresponds to that laid 
between the anterior and septal leaflets of the tricuspid valve (Malouf et al., 2008). The 
commissure between the right and left aortic leaflet contacts its corresponding pulmonary 
ones and overlies the infundibular septum. Finally, the intervalvular fibrosa, at the 
commissure between the left and non-coronary aortic leaflet, fuses the aortic valve to the 
anterior mitral leaflet (Edwards, 1996; Malouf et al., 2008). 
1.2 Physiology of the normal aortic valve  
During left ventricular systole, the systolic pressure inside rises exceeding the aortic 
pressure and the aortic valve is passively opened. Blood, ejected by the left ventricle (LV) 
pushes the aortic cusps upward and away from the centre of the aortic lumen. During this 
phase of cardiac cycle, the major opening diameter of the aortic valve is about equal to that 
of the ascending aorta at the level of sino-tubular junction (Stewart et al., 1998). In fact, the 
relatively inaccurate measurements of LV and intraaortic pressure during left ventricular 
catheterization show that there is no clinically significant gradient across the normal aortic 
valve. This measurement is curious because it suggests that blood does not travel down a 
pressure gradient during ejection. If flow out of the LV and through the outflow tract and 
the aortic valve was simply frictional, then a pressure gradient should needed between the 
LV and ascending aorta to obtain blood flow, according to the low of the physics: 
Q(flow)=Pressure Gradient/Resistance. However, this assumption does not hold when 
considering pulsatile blood flow in large vessels such as the aorta, since the inertia and 
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momentum of the blood ejected from the LV is much more important than resistance. In 
fact, it has been experimentally shown that at the first 40% of the ejection phase, during 
blood acceleration, small pressure gradients (about 10 mmHg) are observed between LV 
and aorta (Hall & Julian, 1989). This small gradient persists for about 45% of the ejection 
after which the gradient reverses as forward blood flow is decelerated. 
The fibrous wall of the sinuses of Valsalva (figure 1) at the nadirs of annular scallops is not 
extensible in contrast to their upper parts (at the level of commissures) where it produces its 
biggest increase of aortic radius, about 16% in the peak of systole, due to the fibro-elastic 
composition of the aortic wall (Williams et al., 1989). During this phase the commissures 
move apart, making the fully open orifice triangular, the free margins of the aortic leaflets 
becoming almost straight lines between commissures. However, they do not flatten against 
the sinus wall, which is an important factor for the subsequent valve closure (Williams et al., 
1989). Most of the blood ejected during systole is directed to the ascending aorta while a 
small volume enters into the sinuses of Valsalva. Valve geometry in the sinus region 
produces vortical blood flow at systole, which helps to coronary perfusion, maintain the 
triangular “mid-position” of the leaflets and probably initiate their re-approximation at the 
end of systole. During diastole, the three aortic leaflets fall passively towards the centre of 
the aortic lumen and, under the pressure of the supravalvular blood column they 
hermetically contact each other along lines of coaptation. Therefore during diastole the three 
normal aortic leaflets, such as the yacht-sails, support the entire intraaortic blood column 
and prevent its partial regurgitation into the left ventricle. Experiments have shown that 
only 4% of blood ejected during systole regurgitates through the centre of the valve during 
diastole. In the absence of sinuses of Valsalva the regurgitant blood may be increased up to 
23% (Williams et al., 1989). 
1.3 The diseased stenotic aortic valve 
Normal aortic valve histology and anatomy may be changed under pathologic conditions 
with corresponding alterations in its normal physiological function. Age-related changes in 
fibromuscular skeleton of the heart include myxomatous degeneration and collagen 
infiltration, called aortic valve sclerosis. This sclerosis is observed in as many as 30% of 
elderly people, namely in 25% of people 65 to 74 years of age and in 48% of people older 
than 84 years (Freeman & Otto, 2005; Otto et al., 1999; Stewart et al., 1997). Histopathologic 
studies of aortic sclerosis show focal subendothelial plaquelike lesions on the aortic side of 
the leaflet that extend to the adjacent fibrosa layer. Similarities to atherosclerosis are present 
in these lesions, with prominent accumulation of “atherogenic” lipoproteins, including LDL 
and lipoprotein(a), evidence of LDL oxidation, an inflammatory cell infiltrate and 
microscopic calcification (Olsson et al., 1999; Otto et al., 1999; Wallby et al, 2002). The 
initiation of these lesions is possibly due to increased mechanical or decreased shear stress, 
similar to that seen in early atherosclerotic lesions (Freeman & Otto, 2005). Of note, these 
changes are more prominent on the aortic surface of the leaflets where the mechanical stress 
of the aortic valve is highest, especially in the flexion area near the attachment to the aortic 
root. Shear stress across the endothelium of the non-coronary cusp is lower than the left and 
right coronary cusps because of the absence of diastolic coronary flow, which likely explains 
why the non-coronary cusp is often the first cusp affected (Freeman & Otto, 2005).  
Other age-related changes become in the valve, in the aortic wall, as well as in the 
myocardium. The central nodules on the cusps and the closure lines become more 
prominent. At the same time the Valsalva’s sinuses are stretched, the diameter of the supra-
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aortic ridge increased and the surface area and mass of the aortic leaflets also increased (Hall 
& Julian, 1989). In the 6th and 7th decades the fibrosa of the leaflet begins to calcify, first at 
the point of attachment to the aortic wall, which is where maximum flexion occurs. This 
calcification may gradually extend throughout the valve, limiting the valve’s opening. 
Occasionally, the calcified leaflets may develop local ulcerations and thrombus formations 
(Otto et al., 1999; Schwartz & Zipes, 2005). Of course, in the cases of the rheumatic disease 
the course of chronic inflammatory disease produce the above-mentioned changes 
(calcification, thickening of the leaflets, fusion of commissures, local ulcerations, sub-
endothelial atherosclerotic plaques, etc.) much earlier. 
In normal adults, the area of the aortic valve orifice is 2.6 to 3.5 cm2. Experimental studies 
have suggested that the aortic orifice must be reduced to approximately one quarter of this 
in order to diminish significantly the cardiac output. A reduction in this area to 1 cm2 is 
associated with a rise in left ventricular systolic pressure and a pressure drop across the 
aortic valve (Hall & Julian, 1989). Aortic stenosis is generally considered to be critical when 
the systolic pressure difference across the valve exceeds 50 mmHg in the presence of a 
normal cardiac output or if the effective aortic orifice is less than 0.4 cm2 (Hall & Julian, 
1989). According to Rahimtoola, the aortic valve area has to be reduced by about 50% of 
normal before a measurable gradient can be demonstrated (Rahimtoola, 2004). When a 
pressure gradient develops between LV and aorta LV pressure is increased, ventricular wall 
stress increased contributing to development of myocardial hypertrophy and the LV 
function impairs. A diastolic dysfunction is caused of a combination of impaired myocardial 
relaxation during diastolic phase and increased myocardial stiffness (Hess et al., 1993). 
Patients with severe LV hypertrophy may exhibit LV diastolic dysfunction, which 
consequently may produce the syndrome of clinical heart failure with symptoms of 
paroxysmal nocturnal dyspnea, orthopnea or even pulmonary oedema, even if the systolic 
LV function is normal (Rahimtoola, 2004).  
Prospective studies on the rate of hemodynamic progression in patients diagnosed with 
aortic stenosis documented an increasing rate of aortic jet velocity, in average 0.3 m/s per 
year, with an increase in mean trans-aortic pressure gradient of 7 mm Hg per year and a 
decrease in aortic valve area of 0.1 cm2 per year (Brener et al., 1995; Faggiano et al., 1996; 
Freeman & Otto, 2005). During this later course, for the cases of symptomatic aortic stenosis 
or of the asymptomatic with significant (> 50 mmHg) trans-valvular mean gradient, surgical 
management is indicated. 
1.4 The surgical management of the stenotic aortic valve 
There are four options for the management of the severe calcific aortic stenosis: the balloon 
aortic valvuloplasty, the “open” aortic valve commissurotomy, the percutaneous aortic 
valve implantation, and the “classic” aortic valve replacement. 
At balloon aortic valvuloplasty (BAV), a ballon-catheter is introduced after a femoral artery 
puncture and retrograde till the left ventricle (Diethrich, 1993; Smedira et al., 1993). Inflation 
of the balloon within the aortic orifice can stretch the calcified annulus, fracture calcified 
areas and dissect the fused commissures. Disadvantages of the method, as the risk of stroke 
and increase of pre-existent valve regurgitation (Cormier & Vahanian, 1992) are controversial 
to increase of effective orifice area. An overall 65% survival and 40% free of death or re-
operation over 1-year survival has been reported (Davidson et al., 1990). However, no 
beneficial effect on long-term clinical outcome demonstrated due to significant residual 
obstruction from leaflet thickening and annular calcification, resulted in severe re-stenosis 
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typically occurred within months (Bonow et al., 1998; Cormier & Vahanian, 1992; Freeman 
& Otto, 2005; Smedira et al., 1993). 
The “open” aortic valvulotomy, performed rarely, usually during another open heart 
operation, is based on the -by a scalpel- commissurotomy of the fused commissure (-s). 
Because of the excessive calcification and rigidity of the leaflets, a central postoperative 
insufficiency is anticipated. The main indication is the case of congenital aortic stenosis with 
one or two congenitally fused commissures. In fact, in young patients, if the valve is pliable, 
mobile, and free of calcification, simple commissurotomy may be feasible. The operative 
mortality in these cases does not exceed 1% (Rahimtoola, 2004).  
The impetus for the development of percutaneous or transcatheter aortic valve 
replacement (PAVI or TAVI) lies in the need for an intervention that is more durable than 
balloon aortic valvuloplasty and that can be used in patients who are too risk for the 
“classic” aortic valve replacement. The basic concept is based on the use of an outer 
expandable stent (scaffold) to resist the rigidity of the calcified aortic annulus and native 
leaflets (Davidson & Baim, 2008). In the inner surface of this stent three appropriately 
prepared pericardial or porcine leaflets are fixed constituting –after full expansion of the 
stent- a well functioning valvular prosthesis. The first implantation in the human being was 
done in France since 1992 by Cribier et al. (Cribier et al., 2002). The introduction of the 
catheter bearing the valved-stent requires direct femoral or iliac artery access, while in a few 
cases with stenotic iliac arteries the catheter is introduced through the apex of the left 
ventricle (transapical introduction), after a left anterior thoracotomy. The results of this 
method after more than 10 years of application are encouraged. Procedural mortality is  
2-3%, one-month survival about 88% and the 1-year is ranged 65 to 78% (Bosmans et al., 
2011).  
Finally, the aortic valve replacement is the “classical” surgical treatment of calcific aortic 
stenosis, especially for the elderly. During this method, the three calcified leaflets of the 
valve are resected, as well as the calcific deposits of the annulus. Then, sutures are passed 
circumferentially through the annulus and the sewing ring of the prosthesis. Finally, the 
sutures are tied down in the native annulus. Aortic valve replacement by using 3rd-
generation prosthetic valves –mechanical or biological- obtains excellent early and late 
outcomes with low mortality and morbidity. Recent surgical series report operative 
mortality rates for aortic valve replacement as low as 1%, increasing to 9% in higher-risk 
patients. Long-term survival after valve replacement is 80% at 3 years, with an age-corrected 
survival postoperatively that is nearly normalized (Freeman & Otto, 2005; Rahimtoola, 
2010). Significant postoperative morbidity, such as thromboembolism, hemorrhagic 
complications from anticoagulation, prosthetic valve dysfunction, and endocarditis, are rare 
and occur at a rate of 2% to 3% per year (Rahimtoola, 2010). 
2. Aortic valve prostheses: The parallel evolution of mechanical & 
bioprosthetic valves  
Cardiac valve prostheses are devices designed and constructed properly to assure 
unidirectional blood flow. Like the natural cardiac valves, they work passively, due to 
pressure difference across their structure, with parts able to be moved between two 
positions: open position, when blood circulates, as in the case of aortic valves from left 
ventricle to the aorta during myocardial contraction (systolic phase) and closed position, 
when blood circulation stops (during the diastolic phase for the aortic valve). From a 
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mechanical point of view, cardiac valves work as common one-way valves of hydraulic 
systems. Despite their simple working principle, the design and orthotopic surgical 
implantation of cardiac valves was not possible till the development of extracorporeal blood 
circulation devices, introduced by Gibbon (Gibbon, 1954), by which blood circulation was 
maintained during open heart surgical procedures. Two main types of prosthetic heart 
valves are available: Mechanical (MHV) and biological or bioprosthetic (BHV) heart valves. 
MHVs in general composed of two main parts: One non-moving, which is sutured properly 
in the anatomic region of the failed, surgically excised, natural valve, in the interior region of 
which a second, moving part is included, passively guided by pressure difference changes 
between the inlet and outlet regions around it. The main difference is on the type of the 
moving part (occluder): The ball type and the disk type valves. For each of the two basic 
constructions many different designs and materials were used and a great branch of 
technology was developed. In a near parallel approach, BHVs, based on mimicking the 
design and function of natural heart valves were developed and applied. Although they 
simply were made of animal derived valves of proper size and structure, like porcine aortic 
valves, after biochemical treatment for removing antigenic factors, different designs have 
been introduced nowadays using combinations of artificial and natural derived 
biomaterials. 
2.1 Evolution of mechanical heart valve prostheses  
Different surgical operations were approached before extracorporeal circulation by 
implantation of artificial valve designs in peripheral vessels, like that of Hufnagel & 
Harvey in 1952 (Hufnagel & Harvey, 1953), when an aortic valve, made by a combination 
of biologically inert materials (a lucite® tube-like design with a mobile spherical poppet 
inside) was implanted in the descending thoracic aorta of a patient with a significant aortic 
insufficiency. However, it was at end of 50s when a caged ball type MHV was introduced. 
This design, in its final appearance, consists of a metallic ring with a soft material in its 
perimeter for stable suturing on surrounding soft tissues without blood leakage through 
the suturing line. A cage design, usually a three metal struts, is welded in the ring into 
which a ball made of silicon or other polymeric material is moved from the closed position, 
where it is pushed in touch with the ring, to the open once where it is attached the top of 
the cage (figure 4a). Starr and co-workers began in 1960 (their first report appeared in 1963) 
(Starr et al., 1963) to implant the caged ball aortic prosthesis in the orthotopic position with 
many of these prostheses remained well functioning for up to 40 years (Shiono et al., 2005). 
Major problems with these initial so-called “ball valves” were the compromised 
hemodynamic performance (small effective orifice area, big size of the sewing ring, 
turbulent flow) and the thromboembolic complications (high-grade haemolysis, 
thrombosis). For the last reason, all these valves required intense anticoagulation therapy 
(Ezekowitz, 2002). 
To find a solution in these problems, after a substitution of ball with a disk type occluder 
(caged disk valves) to achieve less moving mass and reducing the valve height inside the 
aortic root, the second-generation of prosthetic valves, the so-called “tilting-disk valve”, was 
developed in 1968 (Emery et al., 2008) (figure 4b). Tilting disk valves were the result of 
evolution in MHV technology towards reduction of whole volume, occluder mass and 
surface area projected vertical to the blood flow axis, maximizing of opening angle of the 
disk and designed the disk shape so as to approach a near physiological central flow 
velocity profile. Haemocompatibily was also improved by a minimization of the blood 
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contact area, material coating with biocompatible compounds (like pyrolitic carbon) and 
appropriate disk morphology for smoother blood flow around it. The most usable models 
were the Björk-Shiley and the Medronic Hall type. The main problems with these valves 
were the rare rupture of metal strut supporting disk movement and subsequent 
embolisation by the disk, non-axial flow, even in the models of Björk-Shiley with disk 
opening angle of 72°. Due to the excessive turbulent flow through the two orifices of the 
valve (a small and a bigger), a high-grade of haemolysis in patients was reported. However, 
good long-term results characterized that type of MHV (Oxenham et al., 2003). 
The 3rd generation of mechanical valves was appeared in 1977 with the introduction of the 
St. Jude Medical (SJM) bileaflet valve coated with pyrolitic carbon (Emery et al., 2008; Gott et 
al., 2003). Over the following decades, the dramatic step of bileaflet prostheses nearly 
obviated the use of all other kinds of mechanical valves in all over the world (Emery et al., 
2008). In fact, the low-profile SJM valve demonstrated low rates of thomboembolism, low 
trans-valvular gradients, low grade of haemolysis and minimal valvular insufficiency 
(Chambers et al., 2005; Gott et al., 2003; Walther et al., 2000). Out of the SJM valve, several 
other 3rd generation models were introduced such as the ATS Medical Prosthesis, the Sulzer 
CarboMedics , the On-X prosthesis and the Sorin prosthetic valve, all of them with similar 
haemodynamic and clinical outcomes (Chambers et al., 2005; Walther et al., 2000). Since the 
introduction of this 3rd generation of the valves and till over 2.1 million of these models have 
been implanted all over the world. In the meantime, many useful changes in valve design 
have been made in the new models. There are many changes on the effective flow orifice 
area, on the shape of the leaflets (straight, convex or concave), on the pivot style, on the 
angle of orientation of the leaflets (from 72° to 90°), on the sewing-ring etc. (Chambers et al., 
2005; Gelsomino et al., 2002; Gott et al., 2003; Walther et al., 2000).  
 
 
Fig. 4. Three generations of mechanical heart valves: a. caged ball, b. tilting disk & c. bileaflet 
mechanical heart valves 
2.2 Evolution of bioprosthetic heart valves  
Heart valve transplantation is the substitution of the diseased heart valves with healthy 
living heart valves (valves transplanted from genetically similar donors-homologous 
valves), including auto transplantation (the substitution of the aortic valve with the 
pulmonary valve and the later with a prosthetic non-living valve – the Ross procedure). 
Murray in 1956 demonstrated that human aortic valves from cadavers could be used as a 
valve transplant in the descending thoracic aorta in patients with aortic insufficiency 
(Murray, 1956). Based on this research Kerwin and co-workers six years later reported their 
first clinical applications in patients, with one of them having 6-year follow-up (Kerwin et 
a 
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al., 1962). The first orthotopic insertion of homograft valve was performed in 1962 by 
Barratt-Boyes (Barratt-Boyes, 1964). The introduction of other biological valves began in 
1967 when Senning used pieces of fascia lata of the patient for replacement of the diseased 
aortic valve (Senning, 1967; Ionescu & Ross, 1969). 
Xenograft or heterograft valves, animal derived heart valves or BHVs made from different 
animal derived tissues are alternatives, offering the advantage of been prepared much prior 
the operation, available in different sizes and designs. BHVs include a variety of heart valve 
replacement using as substitutes heart valves of different orientations and technologies. 
Among different types, porcine aortic and bovine pericardial xenograft BHVs has been 
established as valve substitutes. Porcine aortic valves, after a treatment for removing excess 
fatty and aortic wall tissue and part of septal myocardial tissue from valve leaflets are 
imposed in biochemical preparation, aimed in removing antigenic factors (valve cells) and 
stabilize the remaining acellular valve tissue against enzyme reactions by different chemical 
compounds. Formaldehyde was first used for porcine valve fixation (Angel, 1972), 
substituted later by glutaraldehyde because of its ability for double-edge cross linking of 
collagen molecules (Woodroof, 1972), resulted in better longevity of valves. The stabilized 
tissue valve is sutured in specially designed frames composed of aortic ring and three 
commissures. A metallic or polymeric frame is used as a skeleton, covered with 
biocompatible textiles (like Teflon® or Dacron®) onto which the valve tissue is sutured with 
permanent sutures). 
Improvement of BHV function was achieved with the use of different membranous soft 
tissues for the construction of valve leaflets and suturing them in similar artificial frames 
like that of the porcine valves. Percutaneous tissue was used for that scope; however, 
pericardial tissue from different animals was finally used alternatively. Pericardial tissue is 
a big membrane enclosing the heart. Its histology is similar to heart valve leaflets with 
respect of its composition of collagen and elastin fiber networks in different layers inside 
an amorhous organic matrix of glycosaminoglycans (GAGs), proteoglycanes (PGs), and 
other proteins. Extracellular water solution of electrolytes and soluble proteins compose 
65-70% of the tissue mass weight. Cells, like fibroblast, epithelial, muscle cells and other 
types are present. Despite these similarities with other soft tissues, including heart valve 
leaflets, fibber structure of bovine pericardium is quite different. Fibber orientation in valve 
leaflets is specified for supporting their motion and strengthening mechanical stress 
developed during valve function. The different anatomic position and function of 
pericardial tissue resulted in a different fibber orientation, varied across its surface. For this 
reason special attention is given in selection criteria of specific regions from the whole 
pericardial membrane for better suitability to function as heart valve leaflets (Simionescu et 
al., 1993). The benefits from the use of pericardial tissue (especially bovine ones, which is 
the standard selection last years) instead of porcine valves were better opening area of the 
valve, coaptation of the valve leaflets and flexibility in design of valve anatomic 
configuration. However, similar problems with porcine BHVs, tissue deterioration and 
calcification still remain. 
The first xenograft valve, a stent-mounted porcine aortic valve was implanted by Binet et al. 
in 1965 (Binet et al., 1965), while the glutaraldehyde-preserved stent-mounted porcine 
valves were introduced by Carpentier et al., in 1967 (Carpentier et al., 1969). Over the past 
40 years, advances in tissue fixation (bovine pericardium and porcine aortic valves) 
methodologies and chemical treatments to prevent calcification, have yielded improvements 
in the longevity of bioprostheses.  
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Like the mechanical valves, the development of biologic valves is characterized by the 
appearance of first-, second-, and third-generation prostheses. First-generation bioprostheses 
were preserved with high-pressure fixation. They include the Medtronic Hancock Standard, 
and the Carpentier-Edwards Standard valves, both porcine prostheses. Second-generation 
prostheses are treated with low-, or zero-pressure fixation. Pericardial prostheses include 
the Carpentier-Edwards Perimount, and the Pericarbon Sorin prostheses. Porcine prostheses 
include the Medtronic Hancock II, the Medtronic Intact, and the Carpentier-Edwards 
Supraannular prostheses. In the third-generation prostheses were included all valves with 
zero-, or low-pressure fixation, decellularization of animal tissues and simultaneous anti-
mineralization processes (e.g. a-amino oleic acid) to reduce material fatigue and 
calcification. In these models the stents have become gradually thinner and flexible, the 
profile much lower and the effective orifice area larger. Porcine prostheses include the 
Medtronic Mosaic, and the St. Jude Medical Epic valve. Pericardial prostheses include the 
Carpentier-Edwards Magna and the Mitroflow Pericardial valve. 
 
 
Fig. 5. Pericardial bioprosthetic heart valve explanted due to severe calcification. A: aortic 
side, b: ventricular side, c: SEM micrograph of the same valve demonstrating calcific crystals 
deposited implemented with leaflet tissue fibber network 
2.3 Comparison of MHV with BHV replacement  
Aortic valve replacement by using a mechanical prosthetic valve is not indicated for all 
patients suffered from aortic valve stenosis. Generally, the two main advantages of the 
mechanical valves are the absence of degeneration (long-term rigidity) and the larger 
effective flow orifice, both contributing to better long-term outcomes. In fact, according to 
many studies followed over time frames, freedom from all-valve related events and from 
the risk of reoperation were improved in patients with mechanical valve prostheses as 
compared to those with biologic prostheses (Ezekowitz, 2002; Gott et al., 2003). On the other 
hand, the main disadvantage of mechanical valves is the obligatory need for long-life 
anticoagulation (Ezekowitz, 2002). The use of porcine BHVs resulted in a better function in 
patient circulatory system, improving failed valve insufficiency due to stenosis or 
regurgitation of diseased natural valves. A central blood flow with a near physiological 
velocity profile, low pressure gradient across the valve, near physiological leaflet 
movements and no need for long term anticoagulation therapy were the benefits of their 
use. However, porcine BHVs longevity remains limited, mainly because of calcification of 
valve leaflets. Calcific crystal deposits are gradually developed in valve leaflets caused 
stiffening and incompetence in their moving ability and valve dysfunction due to stenosis or 
regurgitation. BHV calcification is more often in younger patients, for which MHVs are the 
gold standard in heart valve replacement. 
a b c
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Table 1. Comparison of different types of heart valve substitutes 
A mechanical valve prosthesis is recommended to patients having valve re-operation, 
regardless of the nature of the first operation, as the risk of the second operation is significantly 
higher (Gelsomino et al., 2002; Potter et al., 2005). The most debated age for making decision 
according the selection of type of prosthesis is the decade between 60 and 70 years. The final 
decision is dependent on other parameters, which have to be taken into account, like the 
existence of atrial fibrillation, chronic renal failure, cerebrovascular disease, history of 
gastrointestinal bleeding, contraindication to oral anticoagulants, etc. (Emery et al., 2002). 
In 1962, D. Harken summarized the 10 important characteristics that an ideal heartc valve 
must satisfy: 
1. Not propagate emboli.  
2. Be chemically inert and not damage blood elements. 
3. Offer no resistance to physiological flows. 
4. Close promptly (less than 0.05 second). 
5. Remain closed during the appropriate phase of the cardiac cycle. 
6. Lasting physical and geometric features. 
7. Be inserted in a physiological site, generally the normal anatomical site. 
8. Be capable of permanent fixation. 
9. Not annoy the patient. 
10. Be technically practical to insert (Harken et al., 1962). 
After a near 50 years of evolution today’s mechanical or biological valve do not satisfy all 
those requirements. 
3. Biomechanics of heart valve prostheses  
During their motion natural valve leaflets imposed to different mechanical loading and 
corresponding stress fields. Mechanical bending is developed during opening especially at 
sites near their attachments to valvular ring, while shear stress is gradually developed at 
their sides faced blood flow. A near parabolic velocity profile is produced in fully developed 
central axial blood flow across the valve which fast stabilizes leaflets in a position parallel to 
its axis. Upon starting of closing phase of the valves a reverse leaflet movement is 
Valve type Advantages Disadvantages 
Mechanical • Longevity 
• Easy implantation 
• Variety of size-designs 
• Availability 
• Non physiological geometry - 
hemodynamic 
• Chronic anticoagulation 
therapy 
• Risk of thromboembolism 
• Regular medical 
examinations 
Bioprosthetic • Physiological anatomy - 
hemodynamic 
• Minimize anticoagulation 
therapy 
• Availability 
• Tissue deterioration 
• Calcification 
• Undesirable host reactions 
Living grafts • Ideal anatomy - 
hemodynamic 
• Physiological remodeling 
• Minimal anticoagulation 
therapy 
• Tissue deterioration 
• Calcification 
• Minimal availability 
• Undesirable immunologic 
reactions 
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performed with changing stress fields applied to their structure, till the closing position 
during which these membranous tissues, supported at their sites of attachment on valvular 
rings and their coaptation areas, are imposed in surface tensile loading, while obstructing 
blood backflow and big pressure differences between their sides. As a result of all these 
different mechanical loadings imposed, leaflet tissue is remodelled in a multilaminate, 
anisotropic (see diagram in figure 6) reinforced composite biomaterial, demonstrating a 
structure of multilayered 3D collagen and elastin fibrous networks, integrated and moved 
into an amorphous organic protein matrix, filled with cells and extracellular water, 
electrolytes and soluble proteins of low molecular weight. This tissue structure, different in 
individual valve leaflets, is specifically able to function at the specific anatomic position. 
Been in a different position, like, for example, from pulmonary artery to aorta as in Ross 
procedure, tissue remodelling started to make the pulmonary valve leaflets able to resist 
higher mechanical loading in aortic position, compared with that of pulmonary circulation. 
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Fig. 6. Diagram (from measurements in histological sections) of the laminate and total leaflet 
thickness changed under different pressure levels applied during their fixation with 
glutaraldehyde. In dynamic mode, the valve was under normal function during fixation. 
Anisotropic deformation of the different tissue laminates is demonstrated as pressure increases 
Natural heart valve leaflets exhibit non linear viscoelastic mechanical behaviour under 
mechanical loading (figure 7a). A similar mechanical behaviour is demonstrated by tissue 
heart valves of all species, as well all membranous soft tissues. Chemical modification of 
bioprosthetic heart valves, needed for removing antigenic factors and stabilization against 
enzyme biodegradation, resulted in significant stiffening of leaflet tissue compared with its 
natural state, as demonstrated by increase of high (collagen) modulus (figure 7b). 
Other viscoelastic mechanical parameters of valve leaflet tissue, like low (elastin) modulus 
(the slope of the first linear part of the loading stress-strain curve (fig. 7a)) and relaxation 
index may also changed, although hysteresis, another viscoelastic characteristic of 
membranous soft tissues (defined as the ratio of dissipated to the loading energy in every 
loading-unloading cycle) demonstrating energy dissipation inside the tissue during cyclic 
deformation, measured at 20/35% of loading energy depending on cyclic frequency seems 
to be unchanged after chemical modification. 
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                                            (a)                                                                                 (b) 
Fig. 7. (a) Typical stress-strain diagram of a pericardial tissue under uniaxial tensile cyclic 
loading 0.1 Hz demonstrating non linear mechanical behaviour. EH is the characteristic high 
(collagen) modulus, the tangential modulus of the second linear phase. (b) Collagen 
modulus of fresh natural (BPN) and glutaraldehyde treated (BPG) bovine pericardial tissue 
(mean ± SE) at different cyclic loading rates 
4. Heart valve calcification 
Pathology of natural heart valve calcification causes valve dysfunction (stenosis, 
regurgitation, tissue rupture). A lot of possible aetiologies and mechanisms seem to be 
implemented in its initiation and development in human body tissues. Chronic pathologies, 
infections, metabolism, long term drag therapies and age related tissue degeneration, as well 
biochemical compounds involved in the structure of implanted biomaterials may contribute 
in different ways in growth of different types of calcium phosphate crystals from ions of 
electrolytes diluted in biological fluids, that finally deposited in valve tissue structure 
(Gross, 2003; Schoen & Levy, 2005). However, despite the complicated aetiologies and 
mechanisms of tissue calcification, crystal growth is basically a physicochemical process of 
calcium and phosphate ion crystallization under certain physicochemical conditions that 
may be satisfied during the function of a living organism. 
4.1 Biomineralization: Physicochemical background  
Calcium phosphate deposition on implants may result from the presence of high 
phosphorus levels in the biological fluids in contact with the implanted surface. Due to their 
very low solubility products, a number of phosphate scale minerals may form in aqueous 
supersaturated solutions. In the order of decreasing solubility, they are listed in the 
following table 2. At high solution supersaturations it is possible that a number of precursor 
phases may be formed, depending on the solution pH, which finally transform into the 
thermodynamically more stable HAP, in accordance to Ostwald’s rule of stages which 
predicts that the least stable phase having the highest solubility is formed preferentially 
during a stepwise precipitation process. It is well established that kinetic factors may be 
more important in determining the nature and, hence, the characteristics of the solid 
deposits formed during the precipitation process than the respective equilibrium 
consideration complications that may arise from the formation of mixed solid phases, 
caused of the overgrowth of one crystalline phase over another. 
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Solid Phase Abbrev. Formula Therm.Solub. 
Product 
Dicalcium 
phosphate 
dihydrate 
Dicalcium 
phosphate 
anhydrous 
β.Tricalcium 
phosphate 
Octacalcium 
phosphate 
Hydroxyapatite 
Defect Apatites 
DCPD 
 
 
DCPA 
 
 
TCP 
 
OCP 
 
HAP 
CaHPO4.2H2O 
 
 
CaHPO4 
 
 
Ca3(PO4)2 
 
Ca8H2(PO4)6.5H2O 
 
Ca10(PO4)6(OH)6 
Ca10-x(HPO4)x(PO4)6-x(OH)2-x 
(o≤x≤2) 
1.87x10-7(mol L-1)* 
 
 
9.2x10-7 (mol L-1)* 
 
 
2.8x10-9 (mol L-1)** 
 
2.5x10-99(mol L-1)*** 
 
5.5x10-118 (mol L-1)**** 
Table 2. Calcium phosphate crystalline phases, formulae and corresponding thermo- 
dynamic solubility products. *(Hench & Wilson, 1991), **(Eanes et al., 1965), ***(LeGeros et 
al., 1975), ****(Betts & Posner, 1974) 
The tendency for a particular calcium phosphate phase to form in supersaturated aqueous 
media may be determined from the solubility phase diagrams such as the diagram shown in 
figure 8. It has been reported that when calcium phosphate is precipitated from highly 
supersaturated solutions forms an unstable precursor phase. This phase is characterized by 
the absence of peaks in the powder x-ray diffraction pattern and is known as the amorphous 
calcium phosphate (ACP). The composition of ACP appears to depend upon the 
precipitation conditions and is usually formed in supersaturated solutions at pH >7.0 (Betts 
& Posner, 1974; Eanes et al., 1965; LeGeros et al., 1975; Newesely, 1966). In slightly acidic 
calcium phosphate solutions the monoclinic DCPD is formed (Bets & Posner, 1974; Brown & 
Lehr, 1959). OCP is formed by the hydrolysis of DCPD in solutions of pH 5-6 and may also 
be precipitated heterogeneously upon TCP (Brown et al., 1957). HAP is the 
thermodynamically most stable phase and often, when precipitated in the presence of 
foreign ions, substitution of calcium, phosphate and/or hydroxyls by some of these ions 
take place. Thus, substitutions of OH- by F- or Cl- ions, of the phosphate by sulfate and 
carbonate and of the calcium by Sr2+, Mg2+ and Na+ ions have been reported (Heughebaert 
et al., 1983; Legeros R.Z & Legeros J.P., 1984; Moreno & Varughese, 1981; Nathan, 1984). 
A considerable amount of the work done for the identification of calcium phosphate 
minerals which precipitates spontaneously has been based on the stoichiometric molar ratio 
of calcium to phosphate calculated from the respective changes in the solutions. This ratio 
has been found in several cases to be 1.45±0.05 which is considerably lower than the value of 
1.67 corresponding to HAP which is generally implied as the precipitating mineral. A 
number of different precursor phases have been postulated to be formed including TCP 
(Montel et al., 1981; Narasaraju & Phebe, 1996; Walton et al., 1967), OCP (Eanes & Posner, 
1968, Posner, 1969) and DCPD (Furedi-Milhofer et al., 1976). On the basis of the analysis of 
the induction times preceding the spontaneous precipitation of calcium phosphate, it was 
concluded that at high solution supersaturations the initially forming ACP was converted 
into an apatitic mineral through an OCP precursor phase formation (Fransis & Webb, 1971).  
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Fig. 8. Solubility isothems for calcium phosphate phases at 25°C, Ionic strength 0.1M NaCl 
Spontaneous precipitation investigations have been faced with the problem that at high 
supersaturations the ACP forming initially results in a rapid decrease of the calcium and 
phosphate ion activities which fall bellow the values needed for the spontaneous formation 
of other calcium phosphate phases. A careful analysis of the precipitation of calcium 
phosphate over the pH range 5.0-8.0 suggested that the limiting ion activity product for 
ACP was constant as expected for a discrete mineral phase. Moreover it has also been 
shown that the presence of magnesium in the precipitation medium promoted the formation 
of DCPD at the expense of ACP (Feenstra & de Bruyn, 1979; Posner et al., 1984).  
The driving force for the formation of a solid phase in a continuous aqueous phase is the 
solution supersaturation which can be developed in many ways including temperature 
fluctuation, pH change, mixing of incompatible waters, increasing the concentration by 
evaporation or solid dissolution etc. Although supersaturation is the driving force for the 
formation of a salt, the exact values in which precipitation occurs are quite different from 
salt to salt and as a rule, the degree of supersaturation needed for a sparingly soluble salt is 
orders of magnitude higher than the corresponding value for a soluble salt. For sparingly 
soluble salts Mν+Aν- the supersaturation ratio, S, is defined as: 
 
( ) ( )
( ) ( )
1/
m
m a
M ss
o
s
M A
a IP
S
Ka a
α
ν ν ν
ν ν
α+ −
+ −
+ −
Α
+ −
∞∞
⎧ ⎫ ⎛ ⎞⎪ ⎪= = ⎜ ⎟⎨ ⎬ ⎜ ⎟⎪ ⎪ ⎝ ⎠⎭⎩
 (1) 
where subscripts s and ∞ refer to solution and equilibrium conditions respectively, α denote 
the activities of the respective ions and ν++ν-= ν. IP and osK  are the ion products in the 
supersaturated solution and at equilibrium respectively. 
The fundamental driving force for the formation of a salt from a supersaturated solution is 
the difference in chemical potential of the solute in the supersaturated solution from the 
respective value at equilibrium: 
 sμ μ μ∞Δ = −  (2) 
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Since the chemical potential is expressed in terms of the standard potential and the activity, 
α, of the solute: 
 lnRT aομ μ= +  (3) 
where R and T are the gas constant and the absolute temperature respectively. Substitution 
of eq. (3) to eq.(2) gives for the driving force for solid deposition (Mullin, 1993): 
 ln lns
a
S
RT a
μ
∞
⎛ ⎞Δ = =⎜ ⎟⎝ ⎠
 (4) 
For electrolyte solutions the mean ionic activity is taken: 
 ( )a a ν ν ν ν± + −= = +  (5) 
and 
 
1
,
,
ln lns S
RT
ναμ
α
±
± ∞
⎛ ⎞Δ = =⎜ ⎟⎜ ⎟⎝ ⎠
 (6) 
4.2 Crystal growth in heart valves  
Degeneration of the leaflet tissue, together with calcification constitutes the principal 
reasons for bioprosthetic valve failure (Schoen et al., 1992). Calcification consists as already 
mentioned in the formation of sparingly soluble salts of calcium phosphate due to the 
presence of high levels of calcium and phosphate in blood serum (Schneck, 1995). Although 
the calcific deposits consist of apatitic calcium phosphate (HAP containing mainly 
carbonate, fluoride, magnesium and sodium) the formation of transient precursor phases 
such as DCPD and OCP is possible, as in vitro studies have shown (Brown et al., 1957; 
Heughebaert et al., 1983; Moreno & Varughese, 1981). The formation of calcium phosphates 
on porcine heart valves to a percentage of 30-50% is responsible for their dysfunction after 
12-15 years due to stenosis or insufficiency (Narasaraju & Rao, 1979). 
Despite the fact that the thermodynamic driving force in blood serum for nucleation and 
growth is sufficiently high for the homogeneous formation of calcium phosphates, the 
process is believed to be heterogeneous as dead cell remnants, lipids or degenerative 
collagen fragments may provide active sites for heterogeneous nucleation. Chemical 
treatment of porcine and pericardial bioprosthetic valves with glutaraldehyde is considered 
as one of the main causes of valve calcification (Hammersmeister et al., 1993; Schoen & 
Levy, 1992). Despite intensive research of the past few decades, the mechanism of initiation 
and development of calcific deposits on tissues in contact with blood is still poorly 
understood. As a result the development and production of biological valves resistant to 
calcification is still a major challenge (Grabenwoger et al., 1996; Schoen et al, 1987). 
Biological, chemical and mechanical factors seem to play a significant role in the kinetics of 
the process of calcification (Zipkin, 1970).  
4.3 Models of heart valve calcification  
Heart valve calcification is a slow process, difficult to be studied in vivo in humans. Various 
animal models, like the rat subcutaneous implantation, have been used for simulation of 
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biological environment but in accelerated process conditions, in order to study calcification 
mechanisms. In vitro calcification models have also proposed. These models have the 
advantage of studying the role of isolated or group of parameters that may contribute in 
calcification. Both models are very useful especially as pre-screening methods for studying 
the efficacy of various anticalcification treatments proposed (Bailey et al., 2004; Gross, 2003; 
Kapolos et al., 1997; Krings et al., 2009; Schoen & Levy, 2005). 
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Fig. 9. Experimental set-up for the quantitative investigation of the calcification of heart 
valves in vitro. (A) Automatic titrator apparatus (B) Mounting of heart valves (C) Lid of the 
reactor (Kapolos et al., 1997) 
The use of various model experimental procedures has resulted in the suggestion that the 
calcification is initiated at the matrix vesicles (Anderson, 1983; Wuthier, 1982), by acid 
phospholipids (Boskey, 1981; Boskey & Posner, 1977) or by heterogeneous nucleation of 
various calcium phosphate phases in the body fluids considered as aqueous solutions 
supersaturated with respect to the salts formed (Kim & Trump, 1975; Dallas et al., 1989;, 
Schoen et al., 1985; Brown et al., 1988; Grott et al., 1992). Despite intensive research, it seems 
that there is no agreement on the mechanism of formation of calcific deposits. As a result, 
the evaluations of bioprosthetic materials used for cardiac valve replacements are often met 
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with not unfounded criticism. One of the most successful experimental models presented, 
which is appropriate for the in vitro investigation of mineralization processes is the constant 
supersaturation model introduced and further developed by Nancollas and co-workers 
(Thomson & Nancollas, 1978; Amzad et al., 1978). This methodology allows for the solution 
supersaturation to be kept constant by the addition of titrant solutions. The concentrations 
of the reagents in these solutions are calculated so that full replacement of the precipitated 
mass is ensured. In the case of tests performed on the mineralization of heart valves the 
rates obtained from this system were proportional to the solution’s supersaturation. 
An in vitro model, based in the constant supersaturation model was introduced in 1997 in 
our laboratories for the investigation of heart valve calcification in vitro. The experimental 
set-up is shown in figure 9. Porcine aortic heart valves, treated with glutaraldehyde were 
sutured on Plexiglas® frames to be kept in flat position during stirring. The frames were 
immersed in supersaturated solution with respect to calcium and phosphate ions in near 
physiological concentrations, at 37°C. Solution’s pH drop, associated with initiation of 
crystal growth deposited out of solution, triggered titrant addition with movement of 
computer controlled syringe pumps. 
 
 
Fig. 10. Titrant addition for maintaining constant supersaturation during the course of 
mineralization of artificial heart valves. The rates were increased with increasing solution 
supersaturation (σ=0.72 , 1.09, 1.25 from the lower to the upper curve respectively) 
Figure 10 presents experimental recordings of titrant volume added with time, in order to 
maintain solution’s supersaturation constant. The signal from a pH drop sensitive device 
resulted from the growth of calcium phosphate crystals precipitated out of the solution, 
triggered titrant addition in small time steps. The diagrams correspond to different solution 
supersaturations. The mineral phase deposited on the glutaraldehyde treated porcine valves 
was identified as OCP, hydrolysed partially to HAP. The extent of hydrolysis was larger at 
the lower supersaturations, while at higher supersaturations with respect to OCP, this phase 
was stabilized, as may be seen in the scanning electron micrographs shown in figure11a-c. 
The characteristic plate like crystals are clearly seen in figure 11b.The rates, calculated from 
the titrants addition rates and normalized per unit geometric surface area of the exposed 
valves, were fitted to the semi empirical equation: 
 ( ) ng gR k f S σ=  (7) 
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where kg is the rate constant for crystal growth, f(S) a function of the total number of the 
growth sites available and n the apparent order of the crystal growth process. Logarithmic 
plots according to eq.7 yielded the kinetics shown in figure 12. The practical implications of 
this finding is that the deposition of the mineral phase on the membrane matrix is controlled 
by the diffusion of the growth units on the OCP nuclei been formed. 
 
 
Fig. 11. Scanning electron micrographs of : (a) surface of the valves (b) OCP deposited on the 
valves at higher relative supersaturation and (c) OCP+HAP on valves at low relative 
supersaturation 
Possible strategies aiming at the retardation of the calcification process should therefore rely 
on the alteration of the surfaces so as to make surface integration more difficult. An 
additional feature revealed by the kinetics plots at constant supersaturation (figure 12) is 
that the glutaraldehyde treated porcine valves are substrates favoring the mineral 
nucleation and growth. 
 
 
Fig. 12. Logarithm of the rate of OCP formation on glutaraldeyde treated porcine valves 
(black circles) as a function of the relative solution supersaturation; pH 7.4, 37° C, 0.15M 
NaCl. Open squares and triangles refer to literature results. Experiments performed in our 
laboratory with the same methodology on fresh, untreated porcine valves have shown that 
these tissues failed to induce any formation of calcium phosphate deposits although they 
were kept in the mineralizing solution for as long as four days 
a b c 
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Comparison with data obtained for OCP synthetic crystals (Tomazic et al., 1989) and 
collagen of various types (Heughebaert & Nancollas, 1984; Combes, 1996) showed that 
glutaraldehyde treated porcine valves accelerated the formation of OCP. The significantly 
larger value of the rate constant suggested that in this case the number of active sites is not 
possibly a function of the available surface area. Structural factors on a molecular level 
should also be considered. Calcium phosphate crystal growth and crystal phases 
transformations obtained from the results of our in vitro model have been well correlated 
with similar results obtained from microscopic examinations, chemical analysis and 
spectrophotometric characterization of crystal phases on samples from calcified natural and 
bioprosthetic heart valves (Mikroulis et al., 2002). From the composition, the morphology 
and the size of the developed crystals their nature was determined by comparison with 
reference synthetic calcium phosphate phases. With this technique it was possible to 
determine the morphology of CDs developed at the internal sites of the tissue at high 
magnifications. It seems that in cases of natural heart valves the CDs are mixture of HAP 
(Ca:PO4=1.67) and OCP (Ca:PO4=1.33), while in bioprosthetic CDs the percentage of OCP is 
higher than of native in which the ratio Ca:PO4 (1,82) is close to the Ca:PO4 composition of 
mature physiological biomineral in bone (1,75). 
As an overall conclusion from combined studies examined CDs from calcified valve leaflets 
in vitro, in animal models and in vivo, a model of development of calcification by crystal 
growth through the formation of precursor phases, which are gradually hydrolyzed in 
smaller in size, thermodynamically more stable crystal formations may be introduced. 
According to this, initiation of calcification may be supposed to take place in sites of 
heterogenous nucleation, formed in different tissue deficiencies, together with local changes 
in already highly supersaturated body fluids. This model can be very useful in the 
introduction of anticalcification therapies or techniques for better biomaterials. 
5. Conclusion  
Heart valve calcification is still a serious complication for a great number of patients, 
especially in economical active ages and the elderly. Although anticalcification therapies 
and procedures have been introduced for valve repair, valve replacement, especially that of 
aortic and mitral valves is the last choice. Unfortunately, till today there is no “ideal” aortic 
valve prosthesis. The latter would be easy to be implanted, possess long-term durability, 
would have no thrombogenicity, maximum effective orifice area, without haemolysis, 
“resistant” to infective endocarditis, and produce minima noise (Birkmeyer et al., 2000). 
Currently, available options for the patient include mechanical valve, stented or stentless 
biologic heterograft valves, allograft valves and pulmonary autograft valves. For the 
selection between mechanical and biologic valve the surgeon should balance the risks and 
benefits of each model. The mechanical valve has a long-term durability (till 35-40 years), 
but on the other hand its thrombogenicity is high, 2-4% per year. In addition, the 
administered anticoagulation has a significantly increased risk of bleeding. The biologic 
valve has an increased risk of degeneration, as its durability lasts not more than 10-12 years 
after implantation (Siddiqui et al., 2009). After this time, a significant regurgitation demands 
its replacement with an increased operative mortality in comparison to the initial 
implantation (about two-fold higher). On the other hand, the thrombogenicity of the 
biologic valve is lower than of mechanical ones, about 1% per year (Puvimanasinghe et al., 
2003). Analyses based on mathematical models of data suggest that the selection of 3rd-
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generation biologic valve for patients at about 60 years of age derive improved life 
expectancy and event-free expectancy regardless of the need for concomitant coronary 
artery surgery (Birkmeyer et al., 2000). Of course, for special patient groups the indications 
should be changed. Patients who do need a long-term anticoagulation such as those with 
chronic atrial fibrillation, intracardiac thrombus, history of thromboembolic events, 
hypercoagulable state or low ejection fraction, should receive a mechanical valve regardless 
of age. In the contrary, patients with contraindication to anticoagulants, with bleeding 
disorders, women of child-bearing age, should receive a biologic valve (Bonow et al., 2006). 
Patients with chronic renal failure have a higher risk of earlier bioprosthetic valve 
degeneration, and also an increased incidence of anticoagulation-related complications. For 
that reason, the current ACC/AHA guidelines (2006) do not recommend the routine use of a 
mechanical prosthesis (Bonow et al., 2006). 
6. The future: Tissue engineering (TE)  
Artificial devices designed and manufactured for mid and long term implantation in 
patients has to satisfy quality criteria of biocompatibility and function during all 
implantation time expected. This time period is varied, from a few months, for temporary 
used prostheses, like some orthopaedic fixation plaques and screws, to long life function, as 
in the case of prosthetic heart valves. Despite of their evolution and future trends, even if 
medical technology could make implants satisfying that criteria, prosthetic devices made of, 
in its best, biologically inert biomaterials cannot meet a serious clinical problem: they cannot 
follow changes in patient’s body from the time of implantation to end of their expected life. 
In other words, they cannot grow up and remodelled with patient. Tissue engineering is a 
recent technological approach in the construction of artificial implants that can be gradually 
remodelled into the patient in real living tissue and organs, following regeneration and auto 
repair capabilities similar to that of the other natural patient body components (Kretlow & 
Mikos, 2008; Zilla et al., 2008). Attempts for the construction of TE implants are spread to 
different tissues and organs, like dermal parches, cartilage, bone and cardiovascular 
implants and TE or hybrid organs like pancreas or liver. Design and construction of 
cardiovascular TE implants, like heart valves and blood vessels, is still a challenge because 
of numerous worldwide needs and the severity of possible failure. 
As a general rule TE valves composed of two groups of biomaterials. One group is 
composing the scaffold, a structure having the morphology of natural heart valves, usually a 
biodegradable flexible composite synthetic membrane of a polymeric fibber network 
embedded in amorphous organic matrix. Different structure of valve parts like valve ring, 
wall stent and leaflets give to the synthetic valve mechanical strength and flexibility 
identical to function like natural heart valves. However, scaffolds have a temporary role as, 
in addition and in parallel with their normal physiological function as heart valves, they 
may have the ability to support cell adhesion in their structure. Different cells, like 
fibroblasts, smooth muscle cells and endothelia may adhere, proliferate, stimulated and 
function into the scaffold valve structure to produce different tissue components that will 
synergy to compose suitable valvular tissue. Some of these valve cells are transported into 
scaffold material prior implantation, followed by in vitro cell culture and parallel 
mechanical valve function in special designed devices, bioreactors. A hybrid structure of 
synthetic and living biomaterials is made in vitro, which by implantation in the living 
organism is expected to continue remodelling into real living tissue and organ. As the final 
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form, a natural living heart valve, without any synthetic scaffold components is expected to 
replace the fully biodegraded initially implanted heart valve device (Flanangan & Pandit, 
2003; Ye et al., 2000; Jockenhoevel et al., 2001). Key factors for succession of such an 
approach are: 
• Biocompatibility and mechanical function of scaffold. 
• Rate and products of biodegradation. 
• Functionalization of scaffold to enhance cell adhesion. 
• Selection of initial cell population suitable for in vitro cell culture. Non differentiated 
cells, like bone marrow or umbilical cord derived stem cells, seem to be advantageous 
in responding to biochemical environment and stimulation in bioreactors, towards 
differentiation to cells needed for the in vitro synthesis of initial components of valvular 
tissue. 
Understanding of cell-biomaterial-biomechanics interaction needs a multidisciplinary 
synergism in order to result in successful TE valve, avoiding possible future undesirable 
side effects, like valve failure or carcinogenesis. 
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